RBC cuts CG Oncology to sector perform from outperform; raises target price to $97 from $80
CGON•RBC cut its rating on CG Oncology to sector perform from outperform and raised its target price to $97 from $80.
Related News

Investors cooled on data-center stocks in third quarter, filings show
VRT•

Saba Capital Management reports acquisition of $25,753.90 in New Germany Fund common shares
GF•

MP Materials CFO Ryan Corbett acquires $128,625 in common shares
MP•

Saba Capital reports sale of $172,835.50 in Pimco Dynamic Income Strategy Fund common shares
PDX•

Light & Wonder grants Jamie Odell 16,413 restricted stock units for consulting services
LNW•